Delivery Order SPE2DB22D3004-SPE2DB25FSB44
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,883.59 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered from...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,542.07 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on September 10, 2025, with an ultimate completion date of September 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. HUMIRA is a leading biologic immunosuppressant medication used to treat various...
- The Defense Logistics Agency awarded a delivery order valued at $12,823.53 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on September 12, 2025, with an ultimate completion date of September 15, 2025. This is a firm fixed price, non-competitive delivery order with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. HUMIRA is a widely used...
- The Defense Logistics Agency awarded a $2,265.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 28, 2025, with an ultimate completion date of August 29, 2025. This non-set-aside contract represents a pharmaceutical supply delivery under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery location is...
- The Defense Logistics Agency awarded a delivery order valued at $16,470.37 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on September 8, 2025, with an ultimate completion date of September 9, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic pharmaceutical for treating autoimmune and...
- The Defense Logistics Agency awarded a $13,333.53 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price contract represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune conditions, and this delivery order fulfills immediate pharmaceutical supply...
- The Defense Logistics Agency awarded a $43,110.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with final delivery required by July 15, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $13,700.16 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price contract requires no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely prescribed biologic medication used to treat various inflammatory conditions,...
- The Defense Logistics Agency has awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40 mg/0.8 mL units. This competitively awarded, firm fixed price contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic medication for treating autoimmune conditions including rheumatoid arthritis,...
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FSB44Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded contract employs firm fixed price pricing with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. HUMIRA is a biologic medication commonly used to treat autoimmune and inflammatory conditions, and this delivery order represents a routine pharmaceutical supply transaction under the company's existing federal contract vehicles. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of medications, vaccines, medical devices, and specialized healthcare commodities to support military and veteran healthcare systems. The company's contract portfolio with DLA demonstrates its capability to fulfill federal procurement requirements across multiple therapeutic domains, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 8/19/25 |